Background
==========

Urothelial carcinomas are the most common malignancy of the urinary tract and are derived from the urothelium of the upper urinary tract (renal pelvis and ureter) or lower urinary tract (urinary bladder). Upper urinary tract urothelial carcinomas (UTUCs), in contrast with urinary bladder urothelial carcinomas, are relatively rare, accounting for 2% \~ 8% of urothelial carcinomas \[[@B1]\]. A previous report disclosed that the ratio of incidences of urothelial carcinoma in the renal pelvis, ureter, and urinary bladder was approximately 3:1:51 \[[@B2]\]. However, the prevalence of UTUC is higher in Taiwan, and the ratio was 1:2.08:6.72 in a single institution study in Taiwan that included 535 cases \[[@B3]\]. Due to unknown reasons, the tumor stage of UTUC is high when discovered, which leads to an overall poor prognosis of patients with UTUC \[[@B4]\]. Currently, various prognosticatory factors have been identified, including the tumor stage, lymph node status, growth pattern, tumor necrosis, and lymphovascular invasion. Many molecular markers, such as cadherin-1, hypoxia-inducible factor (HIF)-1α, and telomerase RNA, were also found to independently be associated with tumor recurrence and poor survival \[[@B5],[@B6]\].

Cyclin A is important in regulating cell cycles, including playing roles in initiating DNA replication in the S phase and preventing other cyclins from degrading. Expressions of cyclins are strictly regulated, and degradation of cyclin A in a timely manner is mandatory for the cell cycle to enter metaphase \[[@B7]\]. Overexpression of cyclin A and dysregulation of CDK-cyclin complexes promote tumor cell growth \[[@B8]\]. Cyclin A is also associated with high proliferative activity in various carcinomas, including breast cancer, lung cancer, sarcomas, and hematological malignancies \[[@B9]\]. Furihata et al. demonstrated that overexpression of cyclin A in UTUC is associated with poor cancer-specific survival, the tumor grade, and the tumor growth pattern \[[@B10]\].

HuR, a member of the embryonic lethal abnormal vision (ELAV) protein family, is a turnover- and translation-regulatory RNA-binding protein (TTR-RBP) that regulates the translation and stability of cytoplasmic messenger (m)RNA \[[@B11]\]. HuR was found to be upregulated in almost all malignancies tested, including carcinomas originating in the breast, colon, stomach, pancreas, esophagus, prostate, lung, thyroid, etc \[[@B12]\]. It binds directly to the U- and AU-rich elements in the 3'-untranslated region (UTR) of most target mRNAs, which are termed AREs, or the 5'UTR of some target mRNAs. HuR is predominantly localized in nuclei, but translocation to the cytoplasm is necessary for its regulation upon the expression of target mRNAs. HuR can stabilize many target mRNAs, including those encoding proteins that take part in tumorigenesis or carcinogenesis \[[@B13]\]. Furthermore, translation of several target mRNAs, including cyclin A2, can be upregulated by HuR, although the exact mechanism is still unclear.

Many studies showed that HuR is a prognostic factor in various carcinomas, such as colorectal adenocarcinoma, breast carcinoma, ovarian carcinoma, etc \[[@B14]-[@B16]\]. HuR stabilizes the mRNA of cyclin A2 and increases its translation. Previous studies showed that it plays a critical role in increasing the proliferative activity of colorectal carcinoma, gastric adenocarcinoma, and oral cancer \[[@B17]-[@B19]\]. However, correlations of HuR with biologically and clinicopathologically significant factors of UTUC are unknown.

In this study, by applying an immunohistochemical study to our well-characterized case collection, we evaluated the association of HuR overexpression with clinicopathological parameters and survival of UTUC patients.

Methods
=======

Patients and tumor materials
----------------------------

For the immunohistochemical study and survival analysis, we retrieved data on 340 consecutive patients with primary UTUC, who had received surgical resection with curative intent (ureterectomy, *n* = 10; nephroureterectomy, *n* = 330), from the archives of Chi-Mei Medical Center (Tainan, Taiwan) between 1996 and 2004. Patients who underwent palliative resection and those with a history of previous and/or concurrent urinary bladder cancer were excluded. Patients with suspicion of lymph node metastasis received regional lymph node dissection. Cisplatin-based post-operative adjuvant chemotherapy was performed in 29 out of the 106 patients who had pT3 or pT4 disease or with nodal involvement. The criteria for the clinicopathological evaluation were essentially identical to those described in our previous work \[[@B20]\]. This retrospective clinical and immunohistochemical studies were approved by the institutional review board (IRB971006) of Chi-Mei Medical Center.

Immunohistochemistry for HuR and cyclin A
-----------------------------------------

After preparing and being heated for antigen retrieval as previously described, tissue sections were incubated with primary antibodies against HuR (1:100; Zymed Laboratories, South San Francisco, CA) and cyclin A (6E6, 1:50; Novocastra, Newcastle, UK) for 1 h, followed by antibody detection using a ChemMate EnVision kit (K5001; DAKO, Glostrup, Denmark). Breast carcinoma tissue with known HuR expression in the cytoplasm and cyclin A in nuclei was used as the positive control throughout. Incubation without the primary antibodies was used as the negative control.

Interpretation and scoring of HuR and cyclin A
----------------------------------------------

The immunohistochemical slides were independently interpreted by two pathologists (Y-CW and H-YH), who were blinded to the clinical and pathological results. The cytoplasmic expression of HuR and nuclear labeling of cyclin A in the UTUC were assessed using a combination of the percentage and intensity of positively stained tumor cells to generate a histological score (H-score) \[[@B21],[@B22]\]. The H-score was calculated using the following equation: H-score = ∑ Pi (i + 1), where i is the intensity score (which ranged 0 \~ 4), and Pi is the percentage of stained tumor cells at each intensity (which ranged 0% \~ 100%). This formula produces a score that ranges 100 \~ 500, where 100 indicates that 100% of tumor cells were negative and 500 indicates that 100% of tumor cells were strongly stained (4+).

Follow-up and statistical analyses
----------------------------------

Statistical analyses were performed using the SPSS 14.0 (SPSS, Chicago, IL, USA) software package. The follow-up duration ranged 1 \~ 176 (median, 38) months. Median H-scores of cytoplasmic HuR and nuclear cyclin A were used as the cutoff to dichotomize the study cohort, separating cases into high- and low-expression groups. Associations of HuR and cyclin A expression with various clinicopathological variables were evaluated by a Chi-squared test. The association between HuR and cyclin A results was also evaluated. The end points of the analysis for the entire cohort were the disease-specific survival (DSS), metastasis-free survival (MeFS), and urinary bladder recurrence-free survival (UBRFS) which were calculated from the date of the operation on the UTUC until the presence of disease-related mortality, systemic metastasis developed, and urinary bladder recurrence occurred, respectively, or the last follow-up appointment. Univariate survival analyses were performed using Kaplan-Meier plots, and survival was evaluated by the log-rank test. In the Cox multivariate regression model, all parameters with *p* \< 0.1 at the univariate level were entered to compare their independent prognostic impacts. For all analyses, two-sided tests of significance were used with *p* \< 0.05 considered significant.

Results
=======

Clinicopathological findings
----------------------------

The clinicopathological characters of our patients are listed in Table [1](#T1){ref-type="table"}. The patients' age at diagnosis ranged 34 \~ 87 (median, 68) years. Multifocal tumors were observed in 62 cases. One hundred and forty-one cases (41.5%) had tumors involving the renal pelvis, 150 (44.1%) involving the ureter, and 49 (14.4%) involving both locations. The pT stages of 181 cases were non-invasive (Ta, Figure [1](#F1){ref-type="fig"}A) or early invasive (T1), and the other 159 cases were advanced stages (T2 \~ T4). The majority of cases (*n* = 284, 83%) were high-grade tumors (Figure [1](#F1){ref-type="fig"}B). Lymph node involvement was observed in 28 cases. Most tumors (*n* = 200) were non-invasive or had a nodular invasion pattern and demonstrated low mitotic activity (\<10 per 10 high-power field, *n* = 173), while 58 and 82 cases respectively displayed a trabecular or infiltrative pattern of invasion. In addition, vascular invasion and perineurial invasion were respectively observed in 106 and 19 cases, respectively.

###### 

Correlations between HuR and cyclin A expression and other important clinicopathological parameters

  **Parameter**                                                    **No. of cases**   **HuR Cyto. Exp.**^**†**^   ***p*value**   **Cyclin A Exp.**   ***p*value**         
  ----------------------------------------- ---------------------- ------------------ --------------------------- -------------- ------------------- -------------- ----- -----------
  Gender                                    Male                   182                93                          89             0.664               85             95    0.384
  Female                                    158                    77                 81                                         83                  75                   
  Age (years)                               \<65                   138                72                          66             0.508               75             63    0.185
  ≥65                                       202                    98                 104                                        95                  107                  
  Tumor side                                Right                  177                96                          81             0.201               89             88    0.931
  Left                                      154                    71                 83                                         76                  78                   
  Bilateral                                 9                      3                  6                                          5                   4                    
  Tumor location                            Renal pelvis           141                76                          65             0.374               66             75    0.607
  Ureter                                    150                    73                 77                                         78                  72                   
  Renal pelvis and ureter                   49                     21                 28                                         26                  23                   
  Multifocality                             Single                 278                143                         135            0.261               140            138   0.779
  Multifocal                                62                     27                 35                                         30                  32                   
  Primary tumor (T)                         Ta \~ T1               181                109                         72             \<0.001\*           104            77    0.003\*
  T2 \~ T4                                  159                    61                 98                                         66                  93                   
  Nodal metastasis                          Negative (N0)          312                166                         146            \<0.001\*           159            153   0.237
  Positive (N1 \~ N2)                       28                     4                  24                                         11                  17                   
  Histological grade                        Low grade              56                 37                          19             0.008\*             39             17    0.001\*
  High grade                                284                    133                151                                        131                 151                  
  Pattern of invasion                       Non-invasive/Nodular   200                112                         88             0.030\*             108            92    0.191
  Trabecular                                58                     24                 34                                         27                  31                   
  Infiltrative                              82                     34                 48                                         35                  47                   
  Vascular invasion                         Absent                 234                126                         108            0.035\*             124            110   0.101
  Present                                   106                    44                 62                                         46                  60                   
  Perineurial invasion                      Absent                 321                166                         155            0.009\*             162            159   0.479
  Present                                   19                     4                  15                                         8                   11                   
  Mitotic rate (per 10 high power fields)   \<10                   173                89                          84             0.588               103            70    \<0.001\*
  ≥10                                       167                    81                 86                                         67                  100                  
  Cyclin A expression                       Low                    164                95                          69             0.005\*             \-             \-    \-
  High                                      176                    75                 101                                        \-                  \-                   

^†^ Cyto. Exp., cytoplasmic expression. \* Statistically significant.

![**Histology and immunohistochemistry (HuR and cyclin A) of upper urinary tract urothelial carcinomas.** Representative hematoxylin-eosin-stained sections of a low-stage urothelial carcinoma **(A)** and a high-stage, infiltrating urothelial carcinoma **(B)** which respectively demonstrated low **(C, E)** and high **(D, F)** cytoplasmic HuR and nuclear cyclin A immunoexpressions.](1471-2407-12-611-1){#F1}

Correlations of immunoreactivity of HuR and cyclin A with parameters in UTUC
----------------------------------------------------------------------------

HuR nuclear expression was detected in both normal urothelial cells and UTUCs (Figure [1](#F1){ref-type="fig"}C, D), but HuR cytoplasmic expression was seen in the cancer cells only. The tumors displayed a wide range of H-scores, from 100 to 480 (median, 240). After dichotomizing the tumors into low- and high-HuR expression (Figure [1](#F1){ref-type="fig"}C, D, respectively), as demonstrated in Table [1](#T1){ref-type="table"}, high HuR expression showed a strong association with increments of the pT status (*p* \< 0.001), lymph node metastasis (*p* \< 0.001), a higher histological grade (*p* = 0.008), infiltrative or trabecular pattern of invasion (*p* = 0.030), vascular (*p* = 0.035) and perineurial invasion (*p* = 0.009), and cyclin A expression (*p* = 0.005).

For cyclin A nuclear expression (Figure [1](#F1){ref-type="fig"}E, F), H-scores ranged from 100 to 380 (median, 140). Similarly, high cyclin A expression (Figure [1](#F1){ref-type="fig"}F) was significantly linked to increments in the pT status (*p* = 0.003), a higher histological grade (*p* = 0.001), and frequent mitosis (*p* \< 0.001).

Survival analyses
-----------------

Associations of clinical outcomes with various clinicopathological and immunohistochemical parameters in the univariate analysis are shown in Table [2](#T2){ref-type="table"}. Results showed that a poor DSS was significantly associated with the tumor location (*p* = 0.0079), multifocality (*p* = 0.0026), pT stage (*p* \< 0.0001, Figure [2](#F2){ref-type="fig"}A), lymph node metastasis (*p* \< 0.0001, Figure [2](#F2){ref-type="fig"}C), histological grade (*p* = 0.0215), pattern of invasion (*p* \< 0.0001), vascular and perineurial invasion (both *p* \< 0.0001, Figure [2](#F2){ref-type="fig"}E), high cytoplasmic HuR expression (*p* \< 0.0001, Figure [2](#F2){ref-type="fig"}G), and high nuclear cyclin A expression (*p* = 0.0035, Figure [2](#F2){ref-type="fig"}I). All of these factors, except for the tumor location, were also strongly correlated with a worse MeFS in the univariate analysis (Table [2](#T2){ref-type="table"}, Figure [2](#F2){ref-type="fig"}B, D, F, H, J). For UBRFS, male gender (*p* = 0.0369, Figure [2](#F2){ref-type="fig"}K), higher histological grade (*p* = 0.0056), and cytoplasmic HuR expression (*p* = 0.0370, Figure [2](#F2){ref-type="fig"}L) associated with poor outcome (Table [2](#T2){ref-type="table"}).

###### 

Univariate log-rank analyses for disease-specific, metastasis-free, and urinary bladder recurrence-free survival

                **Parameter**                                       **No. of cases**   **Disease-specific survival**   **Metastasis-free survival**   **UB Recurrence-free survival**                    
  ----------------------------------------- ---------------------- ------------------ ------------------------------- ------------------------------ --------------------------------- ------------ ---- ----------
                   Gender                            Male                 158                       28                            0.8286                            32                    0.7904     43   0.0369\*
                   Female                            182                   33                                                       38                                                      36           
                 Age (years)                         \<65                 138                       26                            0.9943                            30                    0.8470     34    0.5107
                     ≥65                             202                   35                                                       40                                                      45           
                 Tumor side                         Right                 177                       34                            0.7366                            38                    0.3074     44    0.6047
                    Left                             154                   26                                                       32                                                      32           
                  Bilateral                           9                    1                                                        0                                                       3            
               Tumor location                    Renal pelvis             141                       24                           0.0079\*                           31                    0.0659     33    0.1723
                   Ureter                            150                   22                                                       25                                                      32           
           Renal pelvis and ureter                    49                   15                                                       14                                                      14           
                Multifocality                       Single                273                       48                           0.0026\*                           52                   0.0127\*    64    0.1861
                 Multifocal                           62                   18                                                       18                                                      15           
              Primary tumor (T)                    Ta \~ T1               181                       11                          \<0.0001\*                          19                  \<0.0001\*   43    0.2688
                  T2 \~ T4                           159                   50                                                       51                                                      36           
              Nodal metastasis                  Negative (N0)             312                       42                          \<0.0001\*                          55                  \<0.0001\*   73    0.1422
             Positive (N1 \~ N2)                      28                   19                                                       15                                                      6            
             Histological grade                   Low grade                56                        4                           0.0215\*                            3                   0.0027\*    14   0.0056\*
                 High grade                          284                   57                                                       67                                                      65           
             Pattern of invasion             Non-invasive/nodular         200                       19                          \<0.0001\*                          27                  \<0.0001\*   50    0.5398
                 Trabecular                           58                   12                                                       13                                                      14           
                Infiltrative                          82                   30                                                       30                                                      15           
              Vascular invasion                     Absent                234                       24                          \<0.0001\*                          26                  \<0.0001\*   55    0.1770
                   Present                           106                   37                                                       44                                                      24           
            Perineurial invasion                    Absent                321                       50                          \<0.0001\*                          61                  \<0.0001\*   75    0.2169
                   Present                            19                   11                                                       9                                                       4            
   Mitotic rate (per 10 high power fields)           \<10                 173                       27                            0.1607                            30                    0.0823     43    0.9031
                     ≥10                             167                   34                                                       40                                                      36           
            Adjuvant chemotherapy               Not performed             311                       54                            0.4084                            61                    0.2151     70    0.2740
                  Performed                           29                   7                                                        9                                                       9            
         HuR cytoplasmic expression                  Low                  170                       13                          \<0.0001\*                          19                  \<0.0001\*   33   0.0370\*
                    High                             170                   48                                                       51                                                      46           
             Cyclin A expression                     Low                  170                       19                           0.0035\*                           22                   0.0015\*    36    0.3784
                    High                             170                   42                                                       48                                                      43           

\* Statistically significant.

![**Kaplan-Meier plots of disease-specific survival and metastasis-free survival of upper urinary tract urothelial carcinomas.** Kaplan-Meier plots show that the pT stage, nodal status, perineurial invasion, high HuR expression, and high cyclin A expression conferred significant prognostic impacts on both disease-specific survival **(A, C, E, G, I)** and metastasis-free survival **(B, D, F, H, J)**.](1471-2407-12-611-2){#F2}

In the multivariate analysis, as shown in Table [3](#T3){ref-type="table"}, lymph node metastasis (*p* \< 0.001), perineurial invasion (*p* = 0.002), multifocality (*p* = 0.007), the pattern of invasion (*p* = 0.016), and a high histological grade (*p* = 0.026) were related to a dismal DSS. For MeFS, lymph node metastasis (*p* = 0.001), perineurial invasion (*p* = 0.025), multifocality (*p* = 0.024), a high histological grade (*p* = 0.023), and vascular invasion (*p* = 0.002) were correlated with poor outcomes. Male gender (*p* = 0.036) and high tumor grade (*p* = 0.013) significantly associated with worse UBRFS. Interestingly, high HuR expression was significantly correlated with a poor DSS (*p* = 0.038) and MeFS (*p* = 0.027) but not UBRFS (*p* = 0.150). Cyclin A expression did not associate with all three survival outcome.

###### 

Multivariate analyses of disease-specific, metastasis-free, and urinary bladder recurrence-free survival

  **Variable**            **Category**                                            **Disease-specific survival**   **Metastasis-free survival**   **UB Recurrence-free survival**                                                            
  ----------------------- ------------------------------------------------------ ------------------------------- ------------------------------ --------------------------------- ------- ----------------- --------- ------- ------------- ---------
  Nodal metastasis        Positive vs. negative                                               5.602                     2.912 \~ 10.776                     \<0.001\*              3.174   1.648 \~ 6.115    0.001\*    \-         \-          \-
  Perineurial invasion    Present vs. absent                                                  3.291                      1.522 \~ 7.117                      0.002\*               2.460   1.120 \~ 5.401    0.025\*    \-         \-          \-
  Multifocality           Multifocal vs. single                                               2.816                      1.321 \~ 6.004                      0.007\*               2.408   1.124 \~ 5.158    0.024\*    \-         \-          \-
  Pattern of invasion     Infiltrative vs. trabecular vs. non-invasive/Nodular                1.596                      1.090 \~ 2.337                      0.016\*               1.307   0.906 \~ 1.885     0.152     \-         \-          \-
  Histological grade      High grade vs. low grade                                            3.751                     1.170 \~ 12.024                      0.026\*               4.187   1.221 \~ 14.364   0.023\*   2.113   1.173-3.805   0.013\*
  HuR Cyto. Exp.^**†**^   High vs. low                                                        1.996                      1.039 \~ 3.834                      0.038\*               1.880   1.074 \~ 3.291    0.027\*   1.398   0.886-2.204    0.150
  Vascular invasion       Present vs. absent                                                  1.549                      0.823 \~ 2.913                       0.175                2.872   1.486 \~ 5.550    0.002\*    \-         \-          \-
  Cyclin A expression     High vs. low                                                        1.632                      0.909 \~ 2.932                       0.101                1.703   0.994 \~ 2.918     0.053     \-         \-          \-
  Primary tumor (T)       T2 \~ T4 vs. Ta \~ T1                                               1.412                      0.586 \~ 3.400                       0.442                0.916   0.419 \~ 2.003     0.826     \-         \-          \-
  Tumor location          Both renal pelvis and ureter vs. one location alone                 0.950                      0.614 \~ 1.471                       0.819                0.786   0.572 \~ 1.340     0.541     \-         \-          \-
  Mitotic rate            ≥10 vs. \<10/10 hpf                                                  \-                              \-                              \-                  0.849   0.514 \~ 1.402     0.523     \-         \-          \-
  Gender                  Male vs. female                                                      \-                              \-                              \-                   \-           \-            \-      1.607   1.030-2.507   0.036\*

† Cyto. Exp., cytoplasmic expression. \* Statistically significant.

Adjuvant chemotherapy did not significantly improve the DSS, MeFS, and UBRFS when taking all patients into accounted (Table [2](#T2){ref-type="table"}). However, the sub-group analysis for high-risk patients (pT3 or pT4 or with nodal metastasis \[*n* = 106\]) showed that adjuvant chemotherapy significantly improved the DSS (*p* = 0.0228, Figure [3](#F3){ref-type="fig"}A). Besides, high-risk patients with high HuR cytoplasmic expression (*n* = 78) had better DSS if adjuvant chemotherapy was performed (*p* = 0.015, Figure [3](#F3){ref-type="fig"}C). In contrast, the DSS of high-risk patients with low HuR cytoplasmic expression did not improved by adjuvant chemotherapy (*p* = 0.9548, Figure [3](#F3){ref-type="fig"}E). The MeFS showed a trend of improvement, in all high-risk patients (*p* = 0.0817, Figure [3](#F3){ref-type="fig"}B) and those with high HuR cytoplasmic overexpression (*p* =0.0800, Figure [3](#F3){ref-type="fig"}D), but was not statistically significant. Adjuvant chemotherapy had no effect on the MeFS of high-risk patients with low HuR patients (p = 0.7523, Figure [3](#F3){ref-type="fig"}F) and neither UBRFS of high-risk patients, including those with high or low HuR expression (p = 0.3178, p = 0.3870, p = 0.4054, respectively).

![**Kaplan-Meier plots of disease-specific survival and metastasis-free survival of high-risk upper urinary tract urothelial carcinomas (pT3 or pT4 or with nodal metastasis) with or without cisplastin-based adjuvant chemotherapy.** Kaplan-Meier plots show high-risk patients who received cisplastin-based adjuvant chemotherapy conferred significant prognostic impacts on disease-specific survival (DSS) (**A**). The DSS of patients with HuR high expression in tumor cells was significantly improved by adjuvant chemotherapy (**C**). The MeFS was also improved in those with HuR high expression in tumor cells if adjuvant chemotherapy was given but was not statistically significant (**B** and **D**). Adjuvant chemotherapy did not change the DSS and MeFS in the patients with low HuR expression in tumor cells (**E** and **F**).](1471-2407-12-611-3){#F3}

Discussion
==========

Aberrant expression of cancer-related proteins is an essential mechanism in developing malignancies. Protein manufacture can be modified through post-transcriptional mechanisms, such as mRNA splicing, transport, storage, translation, and degradation \[[@B23]\]. TTR-RBPs and noncoding RNA (especially microRNA) are the two main classes of factors which regulate these processes \[[@B24],[@B25]\].

mRNA-binding proteins regulating various essential traits of cell biology underlying tumor aggressiveness is well established. The Hu/ELAV protein family was among the first RBPs that showed an association with carcinogenesis, after Szabo et al. discovered that HuD was a target in small-cell lung cancer-associated paraneoplastic encephalomyelitis \[[@B26]\]. This family is composed of one ubiquitous protein (HuR, also known as HuA) and three neuronal proteins (HuB, HuC, and HuD). As mentioned earlier, HuR is overexpressed in virtually almost all tested malignancies. It stabilizes and/or upregulates the translation of many mRNAs of cancer-related proteins. By regulating target mRNAs of these proteins, HuR expression showed the ability to enhance tumor cell proliferation, increase cell survival and local angiogenesis, evade immune recognition, and promote cancer cell invasion and metastasis \[[@B23]\]. In this study, we demonstrated the expression status and subcellular localization of HuR proteins in a sufficiently large cohort of UTUC cases. For those cases with immunoreactivity above the median score, HuR cytoplasmic expression was significantly correlated with poor outcomes and adverse clinicopathological factors, such as a higher histological grade, an advanced pathological status, the presence of lymph node metastasis, the pattern of invasion, and vascular/perineurial invasion. These findings suggest that HuR expression is associated with carcinogenesis of UTUC and is an important indicator of tumor aggressiveness.

Cyclin A is a crucial component in regulating the cell cycle. Cyclin A binds CDK2 when a cell enters the S-phase to stimulate DNA synthesis. Later, it binds CDK1 when a cell enters the G2 phase to initiate chromosome condensation and possibly nuclear envelope breakdown. It is degraded before a cell enters the M-phase. Overexpression of cyclin A was correlated with a poor prognosis in various malignancies, including lung cancer, breast cancer, sarcoma, and melanoma \[[@B9]\]. Our results show that high cyclin A expression in tumor cell nuclei was correlated with a high pT stage, a higher histological grade, and frequent mitoses. Its associations with DSS and MeFS were significant in the univariate analysis but not the multivariate analysis. These findings are comparable with previous published observations \[[@B10]\]. In addition, increased HuR cytoplasmic expression was correlated with high cyclin A nuclear staining, which was also compatible with what was observed in other cancers \[[@B13]\].

The effect of adjuvant chemotherapy in UTUC is inconclusive. Soga et al. showed that adjuvant chemotherapy with methotrexate, vinblastine, Adriamycin, and Cisplatin could prevent the intravesicle recurrence. \[[@B27]\] Other research groups established that there was no significant survival benefit associated with adjuvant chemotherapy. \[[@B28],[@B29]\] However, our result demonstrated that adjuvant chemotherapy improved the DSS of the high-risk patients (pT3 or pT4 or with nodal involvement) in univariate analysis. Interestingly, we found that the DSS of patients with high HuR cytoplasmic expression in the tumor cells can be improved with adjuvant chemotherapy. This suggests that high HuR cytoplasmic expression might identify a subgroup of patients more likely to be beneficial by adjuvant chemotherapy. Such finding is also in line with pancreatic ductal adenocarcinoma patients. \[[@B30]\] Costantino et al. showed that modulation of the metabolizing enzyme of gemcitabine by HuR overexpression can enhanced the sensitivity of pancreatic cancer cells to the drug. \[[@B31]\] Whether such observation apply on UTUC warrant further studies.

Recently, many molecular markers that are related to cell proliferation, angiogenesis, and apoptosis were tested in UTUC tissues. Some of them proved to be prognosticatory. Snail, Bcl-2, HIF-1a, and metalloproteinases are among those that were correlated with adverse prognostic factors and poor survival \[[@B5],[@B6]\]. Interestingly, mRNAs of all these markers, together with cyclin A, can be stabilized when binding to HuR \[[@B13]\]. In addition, the translation of mRNAs of Snail and HIF-1a is upregulated by HuR. It seems that increased expression of HuR in the cytoplasm of UTUC may stabilize and increase the production of various cancer-related proteins, and thus promote tumor aggressiveness. These may partly explain why HuR but not cyclin A was correlated with the pattern of invasion, vascular invasion, perineurial invasion, and nodal metastasis in our study.

Conclusions
===========

In summary, cytoplasmic HuR expression can be detected in most UTUCs but not normal urothelium, and was significantly associated with adverse clinicopathological factors. Furthermore, cytoplasmic HuR expression was positively related to cyclin A expression and can be used as an independent factor to predict poor DSS and MeFS. High HuR cytoplasmic expression might identify patients more likely to be beneficial for adjuvant chemotherapy. These results suggest that HuR may play an important role in tumorigenesis of UTUCs and confers an aggressive phenotype.
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